Global Tech Times
SEE OTHER BRANDS

The best science and technology news from the world

Global Tech Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Times.

Press releases published on May 5, 2025

Update to Zijin Put Option and Exclusivity Arrangements

Update to Zijin Put Option and Exclusivity Arrangements

TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) refers to its announcement dated 7 April 2025 in relation to the Extension of the Zijin Put Option and Exclusivity Arrangements1 with its major …

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today …

Dundee Precious Metals Announces Passing of Chair R. Peter Gillin

Dundee Precious Metals Announces Passing of Chair R. Peter Gillin

TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announces with great sadness the passing of R. Peter Gillin, Chair of the Company’s Board of Directors since 2022 and a director for the past 16 years …

BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung

BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung

Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1 gerichteter bispezifischer Antikörper, und mRNA- …

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical …

Descartes Sets Date to Announce First Quarter Fiscal 2026 Financial Results

Descartes Sets Date to Announce First Quarter Fiscal 2026 Financial Results

WATERLOO, Ontario and ATLANTA, May 05, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its first quarter fiscal 2026 financial …

BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand

BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand

Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum Finanzvorstand (Chief Financial Officer, „CFO“) …

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, …

Trustable présente son offre d’évaluation cyber des tiers

Trustable présente son offre d’évaluation cyber des tiers

L’éditeur Trustable annonce la disponibilité de sa solution Saas d’évaluation cyber des tiers. La réglementation DORA impose aux institutions financières de renforcer la gestion des risques tiers en s’assurant que leurs prestataires respectent des …

RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located …

Atos Announces SecureHorizons NIS2 Compliance Manager Application Powered by the ServiceNow Platform to Streamline Cybersecurity Efforts

Atos Announces SecureHorizons NIS2 Compliance Manager Application Powered by the ServiceNow Platform to Streamline Cybersecurity Efforts

Press Release Atos Announces SecureHorizons NIS2 Compliance Manager Application Powered by the ServiceNow Platform to Streamline Cybersecurity Efforts First-to-market Application Helps Customers Achieve NIS2 Compliance Through Streamlined, Automated …

Atos annonce le lancement de l'application SecureHorizons NIS2 Compliance Manager sur la plateforme ServiceNow, pour rationaliser les efforts de cybersécurité

Atos annonce le lancement de l'application SecureHorizons NIS2 Compliance Manager sur la plateforme ServiceNow, pour rationaliser les efforts de cybersécurité

Communiqué de presse Atos annonce le lancement de l'application SecureHorizons NIS2 Compliance Manager sur la plateforme ServiceNow, pour rationaliser les efforts de cybersécurité La première application dédiée sur le marché, elle aide les clients à se …

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the …

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R…

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: …

Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros

Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros

Le financement intervient à la suite de la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et à la suite de l’atteinte d’autres conditions préalables.  Daix (France), New York City (New York …

IT News Africa and Infobip Host Webinar to Revolutionize Digital Debt Recovery for BFSI

IT News Africa and Infobip Host Webinar to Revolutionize Digital Debt Recovery for BFSI

JOHANNESBURG, May 05, 2025 (GLOBE NEWSWIRE) -- As Africa’s BFSI sector navigates a rapidly growing lending market, digital debt recovery has become critical for success. Artificial Intelligence (AI) is reshaping this landscape, enabling financial …

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 …

NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALUANT JNJ-1900 (NBTXR3) DANS LE CANCER DU PANCREAS

NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALUANT JNJ-1900 (NBTXR3) DANS LE CANCER DU PANCREAS

Les résultats ont démontré un bon profil de tolérance, une faisabilité d’injection satisfaisante, ainsi que des signaux cliniques encourageants en matière d‘activité antitumorale chez des patients atteints d’un cancer du pancréas localement avancé ou à la …

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service